NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomas - PubMed
5 hours ago
- #immunotherapy
- #high-grade glioma
- #lymphopenia
- NT-I7 (efineptakin alfa) is a long-acting interleukin-7 (IL-7) that increases lymphocyte counts in high-grade glioma (HGG) patients.
- A Phase I trial (NCT03687957) determined the maximum tolerated dose (MTD) of NT-I7 to be 720 µg/kg, with no significant toxicity observed.
- NT-I7 significantly elevated absolute lymphocyte counts (ALC) for over 12 weeks, including CD4+, CD8+ T cells, and NK cells.
- Single-cell RNA sequencing revealed selective clonotype expansion in CD8+ T cells but not CD4+ T cells after NT-I7 administration.
- Some MGMT promoter-unmethylated glioblastoma (GBM) patients showed promising clinical responses, despite typically having poorer prognoses.
- NT-I7 may enhance immune-based therapies and warrants further investigation in combination treatments.